Faron Pharmaceuticals Oy
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FARN.L research report →
Companywww.faron.com
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
- CEO
- Juho Markku Jalkanen
- IPO
- 2015
- Employees
- 25
- HQ
- Turku, FI
Price Chart
Valuation
- Market Cap
- $46.76M
- P/E
- -6.60
- P/S
- 0.00
- P/B
- -2.80
- EV/EBITDA
- -8.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 45.13%
- ROIC
- -96.14%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-27,248,171 · -105024.12%
- EPS
- $-0.25 · -83233.33%
- Op Income
- $-20,260,435
- FCF YoY
- -4.93%
Performance & Tape
- 52W High
- $270.00
- 52W Low
- $38.00
- 50D MA
- $43.95
- 200D MA
- $135.72
- Beta
- 1.11
- Avg Volume
- 148.33K
Get TickerSpark's AI analysis on FARN.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FARN.L Coverage
We haven't published any research on FARN.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FARN.L Report →